top of page


H+ channel inhibitors as anti-cancer drugs

Developing innovative therapeutics by targeting pathways based on 30+ years of research at the University of Geneva

ABOUT US
HPlus is developing innovative therapeutics by targeting pathways based on more than 30 years of research at the University of Geneva. The company’s sole focus is the study of the Hv1 proton channel.
1.4 million CHF of grant funding already raised. HPlus is now seeking 1 million CHF to continue HIT to LEAD phase and to secure IP protection. First disease indication: Granulocytic Sarcome

About us


TEAM
Team

Dr. Zhukovsky, Dr. Niquille,
Dr. Brun, Dr. Mosser

Dr. Chemaly

Mr. Cambet

Prof. Demaurex

Dr. Jaquet

Prof. Krause
Contact
bottom of page